Smith J, Ng D, Alvarez C, Egner P, Burke S, Chen J
Toxins (Basel). 2022; 14(3).
PMID: 35324659
PMC: 8954427.
DOI: 10.3390/toxins14030162.
Koller A, Grzegorzewski J, Konig M
Front Physiol. 2021; 12:757293.
PMID: 34880776
PMC: 8646094.
DOI: 10.3389/fphys.2021.757293.
Ferrandino G, Orf I, Smith R, Calcagno M, Thind A, Debiram-Beecham I
Clin Transl Gastroenterol. 2020; 11(9):e00239.
PMID: 33094960
PMC: 7498135.
DOI: 10.14309/ctg.0000000000000239.
Dutta H, Rao D, Gupta D
Afr J Paediatr Surg. 2019; 15(1):5-9.
PMID: 30829301
PMC: 6419554.
DOI: 10.4103/ajps.AJPS_78_16.
Levitt D, Levitt M
Int J Gen Med. 2016; 9:229-55.
PMID: 27486341
PMC: 4956071.
DOI: 10.2147/IJGM.S102819.
Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease.
Levitt D, Levitt M
Clin Exp Gastroenterol. 2014; 7:307-28.
PMID: 25214800
PMC: 4159128.
DOI: 10.2147/CEG.S64283.
Preclinical lymphatic imaging.
Zhang F, Niu G, Lu G, Chen X
Mol Imaging Biol. 2010; 13(4):599-612.
PMID: 20862613
PMC: 3164973.
DOI: 10.1007/s11307-010-0421-y.
In vivo fluorescence imaging: a personal perspective.
Ghoroghchian P, Therien M, Hammer D
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 1(2):156-67.
PMID: 20049787
PMC: 3091504.
DOI: 10.1002/wnan.7.
Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.
Mayersohn M, Guentert T
Clin Pharmacokinet. 1995; 29(5):292-332.
PMID: 8582117
DOI: 10.2165/00003088-199529050-00002.
Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
Fabre D, Bressolle F, Gomeni R, Bouvet O, Dubois A, Raffanel C
Clin Pharmacokinet. 1993; 24(4):333-43.
PMID: 8491059
DOI: 10.2165/00003088-199324040-00006.
Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer L, OSullivan T, Reiss W, Horn J, Opheim K, Strandness D
Br J Clin Pharmacol. 1994; 37(4):375-81.
PMID: 8018459
PMC: 1364739.
DOI: 10.1111/j.1365-2125.1994.tb04292.x.
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.
Barbhaiya R, Shukla U, Pfeffer M, PITTMAN K, Shrotriya R, Laroudie C
Eur J Clin Pharmacol. 1994; 46(1):41-7.
PMID: 7911763
DOI: 10.1007/BF00195914.
Antipyrine clearance in patients with Gilbert's syndrome.
Ishizaki T, Chiba K, Sasaki T
Eur J Clin Pharmacol. 1984; 27(3):297-302.
PMID: 6510457
DOI: 10.1007/BF00542163.
Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.
Reichen J, Le M
J Clin Invest. 1986; 78(2):448-55.
PMID: 3734100
PMC: 423578.
DOI: 10.1172/JCI112596.
Drug disposition in patients with HBsAg-positive chronic liver disease.
Villeneuve J, Thibeault M, Ampelas M, LAMARRE L, Cote J, Pomier-Layrargues G
Dig Dis Sci. 1987; 32(7):710-4.
PMID: 3595383
DOI: 10.1007/BF01296136.
Antipyrine kinetics in liver disease and liver transplantation.
Mehta M, Venkataramanan R, Burckart G, Ptachcinski R, Yang S, Gray J
Clin Pharmacol Ther. 1986; 39(4):372-7.
PMID: 3514052
PMC: 2954767.
DOI: 10.1038/clpt.1986.57.
Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.
van Harten J, van Brummelen P, Wilson J, Lodewijks M, Breimer D
Eur J Clin Pharmacol. 1988; 34(4):387-94.
PMID: 3402524
DOI: 10.1007/BF00542441.
Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.
Moore M, Erlichman C
Clin Pharmacokinet. 1987; 13(4):205-27.
PMID: 3311530
DOI: 10.2165/00003088-198713040-00001.
Pharmacokinetics of biliary excretion in man. VI. Indocyanine green.
Meijer D, Weert B, Vermeer G
Eur J Clin Pharmacol. 1988; 35(3):295-303.
PMID: 3181282
DOI: 10.1007/BF00558268.
D-sorbitol clearance.
Merkel C, Gatta A
Dig Dis Sci. 1988; 33(10):1341.
PMID: 3168704
DOI: 10.1007/BF01536692.